With international travel, "any outbreak, anywhere in the world can be a threat, everywhere." That's the reality of an increasingly connected world, said Malik Peiris, PhD, of the School of Public Health at the HKU-Pasteur Research Center, The University of Hong Kong, Pokfulam, Hong Kong, at IDWeek 2016.
Long-term use of proton pump inhibitors (PPIs) might increase microbial translocation and innate immune activation but not enterocyte turnover or T-cell activation among people infected with HIV-1, according to research findings reported at IDWeek 2016.
GSK Vaccines' investigational meningococcal vaccine against serogroups A, B, C, W and Y (MenABCWY) is broadly effective among adolescents, according to the company's phase 2b, observer-blind, multicenter study, reported at IDWeek 2016.
HIV and hepatitis B virus (HBV) drugs had no impact on antiviral activity of grazoprevir or elbasvir, and neither agent affected HIV and HBV replication, a study presented at IDWeek has shown.
Together, depression and HIV infection are "strongly associated" with all-cause mortality in U.S. veterans, results from one of the largest analyses to date to examine this association reported at IDWeek 2016.
In children with cancer, concurrent vancomycin and piperacillin-tazobactam administration may increase risk of acute kidney injury, a retrospective study presented at IDWeek has shown.
Extended-interval aminoglycoside dosing "appears of be safe in pediatric patients," a retrospective study presented at IDWeek has found.
The overall risk of hepatic decompensation in patients treated with the paritaprevir/ritonavir, ombitasvir, dasabuvir (PrOD) regimen during and up to 12 weeks after completion of treatment was low, Adeel A. Butt, MD, MS, of the VA Pittsburgh Healthcare System, Pittsburgh, PA, told IDWeek 2016 attendees.
Opportunities to vaccinate against Hepatitis A virus were missed in more than half of patients with HIV and Hepatitis C virus co-infection, researchers reported at IDWeek 2016.
Use of protease inhibitors was associated with higher rates of liver aminotransferase elevations in patients with HIV; however, severe acute liver injury was uncommon with all antiretroviral therapy (ART) regimens, concluded a retrospective cohort study presented at IDWeek 2016.
Minocycline "may be a good choice" for infections caused by Stenotrophomonas maltophilia, "an inherently resistant organism with limited treatment options," concluded authors of a retrospective study presented at IDWeek.
Overall sustained virologic response (SVR) rate for ledipasvir/sofosbuvir in hepatitis C virus (HCV)/HIV co-infected patients in real world settings was 95.2%.
Relebactam (MK-7655) restored imipenem activity against many respiratory tract infection isolates from the US and Canada, researchers reported at IDWeek 2016.
For patients with hepatitis C virus (HCV) infection genotype (GT) 1-6, treatment with sofosbuvir/velpatasvir plus voxilaprevir (GS-9857) once daily was safe, well tolerated, and highly effective in treatment-naive and treatment-experienced patients, reported Ronald Nahass, MD, FIDSA, FSHEA, from ID Care, Inc., Hillsborough, NJ, at IDWeek 2016.
An age- and gender-based pooled analysis presented at IDWeek 2016 showed that delafloxacin had comparable outcomes to vancomycin at 48-72 hours for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
The investigational anti-HIV integrase inhibitor cabotegravir (CAB) is well-tolerated, according to a meta-analysis of clinical trial data reported at IDWeek 2016.
Trimethoprim-sulfamethoxazole (TMP-SMX) or clindamycin treatment following small abscess incision and drainage (I&D) improves outcomes.
A total of 2,538 patients taking piperacillin/tazobactam and 1,134 patients taking levofloxacin were included in the analysis.
GSK's investigational combined measles, mumps, and rubella (MMR) vaccine (GSK_MMR) "demonstrated an acceptable immune response" that was non-inferior to Merck's MMR vaccine (MRK_MMR), a multinational, randomized, Phase 3A, controlled, observer-blinded study reported at IDWeek 2016 has shown.
Children presenting with outpatient influenza-like illness rarely received an antiviral prescription, according to a retrospective cohort study presented at IDWeek 2016.
Combined daily dolutegravir (DTV, 50 mg) and rilpivirine (RPV, 25 mg) is safe for HIV-infected patients previously treated with other regimens, according to findings from a small observational retrospective study reported at IDWeek 2016.
An investigational herpes zoster subunit vaccine significantly reduces disease risk as well as severity in those who develop breakthrough disease in adults 50 years and older
Population level-analyses between 2003-2013 found no links between sudden infant death syndrome (SIDS), attention-deficit/hyperactivity disorder (ADHD), and vaccines, Jana Shaw, MD, MPH, Associate Professor of Pediatrics, Pediatric Infectious Diseases, Upstate Golisano Children's Hospital, State University of New York, Syracuse, NY, presented at IDWeek 2016.
Intravenous and oral delafloxacin (DLX) monotherapy, an investigational, full-spectrum anionic fluoroquinolone, exhibits tolerability and efficacy comparable to those for vancomycin/aztreonam (VAN/AZ) among adult patients with acute bacterial and skin structure infections (ABSSSI), including MRSA and gram-negative infections.
Compared to multi-pill antiretroviral therapy (ART), 1-pill ART is associated with improved likelihoods of initial and sustained virologic suppression among HIV-positive young people, according to findings from a retrospective multiinstitutional analysis reported at IDWeek 2016.
During the 2013-2014 A/H1N1 dominant flu season, Fluzone High-Dose vaccine reduced the risks of all-cause hospitalization and hospitalization for respiratory conditions among long-term care residents compared with Fluzone standard-dose vaccine, investigators reported at IDWeek.
Concerns about administering live, attenuated influenza vaccine (LAIV) in children with asthma "may not be warranted," concluded authors of a study presented at IDWeek.
Both the tablet and intravenous (IV) formulations of posaconazole appeared to be safe and effective for primary prophylaxis against invasive fungal infections in patients with hematologic malignancies, according to results of a retrospective cohort study presented at IDWeek 2016.
Antibiotics overprescribing for patients with community-acquired pneumonia is a persisting and significant problem in the ICU, researchers reported at IDWeek 2016.